Neuromuscular

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor in the Department of Chemistry and Biochemistry at University of Nevada, Las Vegas reflected on receiving the first MDA Research Momentum Award at the 2026 MDA Conference. [WATCH TIME: 2 minutes]

The director of the autoimmune neurology program at the University of Colorado discussed data she presented at AAN's 2026 Meeting [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

In the phase 3 NIMBLE trial, Cemdisiran met primary and secondary endpoints, demonstrating rapid and sustained improvements in MG-ADL and QMG scores with once-every-12-week dosing in AChR-positive generalized myasthenia gravis.

In the global phase 3 PREVAIL trial, gefurulimab met primary and secondary endpoints in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, potentially offering a more convenient alternative to intravenous therapies.

Data show ofatumumab maintains a steady safety profile in relapsing MS, with low serious infections, stable labs, and durable biomarker improvements.

In a 58-week open-label extension, most patients with Parkinson disease treated with tavapadon avoided starting levodopa or required no dose increases, suggesting a potential levodopa-sparing effect.

A phase 3, double-blind study is assessing telitacicept in generalized myasthenia gravis, following prior trials that demonstrated substantial improvements in functional and strength-based clinical outcomes.

The senior global medical director at Sanofi discussed the ongoing burden of CIDP, highlighting diagnostic challenges, treatment gaps, and the need for improved biomarkers and emerging therapies. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Semaglutide shows CNS biomarker shifts in early Alzheimer disease, lowering CSF tau and neurogranin while reshaping immune signals, as per new AAN data report.

Week-52 data from the phase 3 MINT trial show sustained improvements in MG-ADL and QMG scores with inebilizumab in patients with AChR-positive generalized myasthenia gravis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Alexander Shustorovich, DO, an interventional pain medicine physician, discussed a unique case of sustained pain relief after spinal cord stimulation trial and its implications for neuromodulation strategies.

Here's some of what is coming soon to NeurologyLive® this week.

Diana Castro, MD, founder and director of the Neurology and Neuromuscular Care Center, discussed early phase 1b data on salanersen, an investigational therapy for patients living with spinal muscular atrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

The director of Neuromuscular Medicine at Children’s Hospital of The King’s Daughters discussed the phase 4 RESPOND trial and how add-on nusinersen may improve motor function and biomarker outcomes in patients with spinal muscular atrophy following gene therapy.

The chief research officer of the Muscular Dystrophy Association spoke on the FDA's approval of a high-dose regimen of nusinersen and how it fits into an increasingly complex treatment landscape. [WATCH TIME: 11 minutes]

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

Following the FDA approval of tividenofusp alfa, this piece explores the evolving Hunter syndrome treatment landscape and highlights key pipeline therapies targeting both systemic and CNS disease burden.